Skip to main content
CSPC Pharmaceutical Group Limited (FRA:CVG)
Germany flag Germany · Delayed Price · Currency is EUR
0.6800
-0.0012 (-0.18%)
At close: May 2, 2025, 10:00 PM CET

Revenue by Product

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Total Finished Drugs
23.72B
Log In
Log In
Log In
Log In
Total Finished Drugs Growth
-7.36%
Log In
Log In
Log In
Log In
Vitamin C
1.99B
Log In
Log In
Log In
Log In
Vitamin C Growth
3.36%
Log In
Log In
Log In
Log In
Antibiotics
1.59B
Log In
Log In
Log In
Log In
Antibiotics Growth
-7.19%
Log In
Log In
Log In
Log In
Total Bulk Products
3.58B
Log In
Log In
Log In
Log In
Total Bulk Products Growth
-1.60%
Log In
Log In
Log In
Log In
Functional Food and Others
1.69B
Log In
Log In
Log In
Log In
Functional Food and Others Growth
-22.18%
Log In
Log In
Log In
Log In
Nervous System
9.65B
Log In
Log In
Log In
Log In
Nervous System Growth
6.12%
Log In
Log In
Log In
Log In
Oncology
4.40B
Log In
Log In
Log In
Log In
Oncology Growth
-28.33%
Log In
Log In
Log In
Log In
Anti-Infectives
4.09B
Log In
Log In
Log In
Log In
Anti-Infectives Growth
-3.54%
Log In
Log In
Log In
Log In
Cardiovascular
2.08B
Log In
Log In
Log In
Log In
Cardiovascular Growth
-14.80%
Log In
Log In
Log In
Log In
Respiratory System
1.20B
Log In
Log In
Log In
Log In
Respiratory System Growth
-23.14%
Log In
Log In
Log In
Log In
Digestion and Metabolism
1.05B
Log In
Log In
Log In
Log In
Digestion and Metabolism Growth
18.22%
Log In
Log In
Log In
Log In
Other Therapeutic Areas
1.26B
Log In
Log In
Log In
Log In
Other Therapeutic Areas Growth
0.72%
Log In
Log In
Log In
Log In
Licence Fee Income
17.83M
Log In
Log In
Log In
Log In
Licence Fee Income Growth
-
Log In
Log In
Log In
Log In

EBIT by Product

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Finished Drugs Segment Profit
4.83B
Log In
Log In
Log In
Log In
Finished Drugs Segment Profit Growth
-27.95%
Log In
Log In
Log In
Log In
Vitamin C Segment Profit
211.28M
Log In
Log In
Log In
Log In
Vitamin C Segment Profit Growth
4168.26%
Log In
Log In
Log In
Log In
Antibiotics Segment Profit
299.18M
Log In
Log In
Log In
Log In
Antibiotics Segment Profit Growth
93.83%
Log In
Log In
Log In
Log In
Total Bulk Products Segment Profit
510.45M
Log In
Log In
Log In
Log In
Total Bulk Products Segment Profit Growth
220.44%
Log In
Log In
Log In
Log In
Functional Food and Others Segment Profit
305.29M
Log In
Log In
Log In
Log In
Functional Food and Others Segment Profit Growth
-45.63%
Log In
Log In
Log In
Log In

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Mainland China
25.11B
Log In
Log In
Log In
Log In
Mainland China Growth
-
Log In
Log In
Log In
Log In
Other Asian Regions
1.18B
Log In
Log In
Log In
Log In
Other Asian Regions Growth
-
Log In
Log In
Log In
Log In
Americas
-
Log In
Log In
Log In
Log In
Americas Growth
-
Log In
Log In
Log In
Log In
Europe
1.31B
Log In
Log In
Log In
Log In
Europe Growth
-
Log In
Log In
Log In
Log In
Other Geographies Revenue (Pre-FY2023 Reporting)
-
Log In
Log In
Log In
Log In
Other Geographies Revenue (Pre-FY2023 Reporting) Growth
-
Log In
Log In
Log In
Log In
North America
853.04M
Log In
Log In
Log In
Log In
North America Growth
-
Log In
Log In
Log In
Log In
Other Geographies
553.88M
Log In
Log In
Log In
Log In
Other Geographies Growth
-
Log In
Log In
Log In
Log In